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Reduced neonatal brain-derived neurotrophic
factor is associated with autism spectrum disorders
Kristin Skogstrand 1,2, Christian Munch Hagen1,2, Nis Borbye-Lorenzen 1,2, Michael Christiansen1,2,3,
Jonas Bybjerg-Grauholm 1,2, Marie Bækvad-Hansen1,2, Thomas Werge2,4,5, Anders Børglum 2,6,7,8, Ole Mors2,9,10,
Merethe Nordentoft2,11, Preben Bo Mortensen2,3,6,12 and David Michael Hougaard 1,2
Abstract
Mental disorders have for the majority of cases an unknown etiology, but several studies indicate that
neurodevelopmental changes happen in utero or early after birth. We performed a nested case–control study of the
relation between blood levels of neuro-developmental (S100B, BDNF, and VEGF-A) and inﬂammatory (MCP-1, TARC, IL-
8, IL-18, CRP, and IgA) biomarkers in newborns, and later development of autism spectrum disorders (ASD, N= 751),
attention deﬁcit hyperactivity disorders (ADHD, N= 801), schizophrenia (N= 1969), affective (N= 641) or bipolar
disorders (N= 641). Samples and controls were obtained as part of the iPSYCH Danish Case–Cohort Study using dried
blood spot samples collected between 1981 and 2004, and stored frozen at the Danish National Biobank. In newborns
lower blood level of BDNF was signiﬁcantly associated with increased odds (OR 1.15) of developing ASD (p= 0.001).
This difference could not be explained by genetic variation in the BDNF coding gene region. A tendency of decreased
levels of all the neurotrophic markers and increased levels of all inﬂammatory markers was noted. The low newborn
blood levels of BDNF in children developing ASD is an important ﬁnding, suggesting that lower BDNF levels in
newborns contributes to the etiology of ASD and indicates new directions for further research. It may also help
identifying a long-sought marker for high-ASD risk in, e.g., younger siblings of ASD children.
Introduction
Autism spectrum disorders (ASD), attention deﬁcit
hyperactivity disorder (ADHD), schizophrenia, affective-
and bipolar disorders are all mental disorders with, for
most cases, a largely unknown etiology1–5.
ASD and ADHD are normally diagnosed in childhood.
ASD is a group of developmental disorders with qualita-
tive abnormalities in reciprocal social interaction, com-
munication and restricted, repetitive, and stereotyped
patterns of behavior, interests, and activities. The symp-
toms of the disorders exhibit a high degree of variation,
and their severity varies considerably6. ADHD is the most
frequent mental diagnosis among children and is char-
acterized by hyperactivity, impulsivity, and inattention7.
Schizophrenia and affective disorders are mainly diag-
nosed in youth and adulthood. Schizophrenia is a syn-
drome of symptoms characterized by psychosis, social
withdrawal, and difﬁculties with social interactions8, and
is generally accepted as not being a single disorder5.
Affective disorders are a set of mood (affective) disorders9,
where bipolar disorder is a sub group characterized by
repeated episodes in which mood and activity levels are
signiﬁcantly disturbed by an elevation of mood, increased
energy and activity or of a lowering of mood and
decreased energy and activity10.
The patients often have more than one of the diagnoses,
and the symptoms—as well as genetic architecture—
overlap11–15. A recent study using structural magnetic
resonance imaging of the brain in children has shown
similar patterns between ASD and ADHD16. The mean
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life-time risk for the investigated disorders are 2.0% for
ASD, 3.2% for ADHD, 1.8% for schizophrenia, 13.2% for
affective disorders, and 1.6% for bipolar disorders17. ASD,
schizophrenia, and ADHD are more often seen in
monozygotic than in dizygotic twins, indicating strong
genetic effects, and are more prevalent in males18–20. The
heterogeneity of the disorders makes it difﬁcult to eluci-
date their pathogenesis, which most probably is multi
etiological2–5. Several causes of these disorders have been
suggested: prenatal and early life stress21, brain synaptic
dysfunctions22, early life exposure to metals23, perinatal
hypoxia24, preterm birth25, neuro-inﬂammation26, neo-
natal infection27, maternal viral-infections28, maternal
immune activation29, gut–microbe–brain–immune axis30,
and genetic factors31 are all considered plausible expla-
nations. Meta-analyses indicate that a combination of
environmental and genetic factors, as well as both peri-
natal and neonatal factors, increase the risk3,32,33. The
mechanisms of the neurodevelopmental defects are
unknown, but a change in neuron synapse formation (i.e.,
a change in connections between brain areas) may be a
part of the explanation29. There has been considerable
research in the area, but no clinically relevant biomarker
or speciﬁc risk factor has yet been identiﬁed34–37.
As inﬂammation is involved in several of the suggested
causes for mental disorders, our aim in the current study
was to explore the possible role that inﬂammation/infec-
tion may play in the developing brain of newborns. Fur-
ther, we wanted to explore if different neurotrophic
factors in newborns may contribute to the understanding
of the etiology of mental disorders. The Danish Neonatal
Screening Biobank makes it possible for us to analyze the
dried blood spot samples (DBSS) drawn from all children
5–7 days after birth for neonatal screening38. We have
previously developed multiplex analytical methods for
these samples39,40 and have demonstrated that it is pos-
sible to measure a number of biomarkers in DBSS stored
at −24 °C for more than 30 years41–43. As part of the
Lundbeck Foundation Initiative for Integrative Psychiatric
Research (iPSYCH)44, we selected cases and controls
matched by birth year from the iPSYCH Danish
Case–Cohort Study from newborns, where cases were
diagnosed with ASD (801 cases and 2421 controls),
ADHD (751 cases and 2423 controls), schizophrenia
(1969 cases and 2681 controls), bipolar- (641 cases and
2311 controls), and affective (641 cases and 2371 controls)
disorders. Nine biomarkers were selected, based on earlier
described studies either as a promising biomarker for one
or more of the disorders, or as a marker that indicate
either brain damage or inﬂammation34. The following
markers were selected to explore neuronal development:
S100 calcium binding protein B (S100B), brain-derived
neurotrophic factor (BDNF), and vascular endothelial
growth factor A (VEGF-A), and to indicate neonatal
inﬂammation/infection: monocyte chemotactic protein-1
(MCP-1), thymus and activation-regulated chemokine
(TARC), interleukin-8 (IL-8), IL-18, C-reactive protein
(CRP), and immunoglobulin A (IgA).
To further explore signiﬁcant ﬁndings, we examined the
genetic inﬂuence on the measured biomarker levels using
SNPs from GWAS imputed data in the coding region of
the BDNF gene. We also tested for association between
genetic clusters, generated using principal component
analysis and K-means clustering, and BDNF blood levels.
In addition, correlation between BDNF and the other
measured biomarkers were investigated.
Methods
Sample selection
Samples were selected from the iPSYCH cohort of 86
189 individuals44. Table 1 shows the ICD-10 codes for the
cases, and the numbers, distribution and demographic
data for cases and controls for each disorder. Most of the
controls were used as controls for several case groups,
and some of the cases have multiple diagnosis and thus
are cases in more than one group. Controls were chosen
at random from the entire Danish population and were
matched with cases on birth year. In order to control for
population stratiﬁcation and cryptic relatedness effects
on marker levels, which refers to the idea that some
members of a case–control sample might be close rela-
tives, in which case their genotypes are not independent
draws from the population frequencies45, ﬁrst- and
second-degree relatives were removed, please see “Sta-
tistics” for details. The distribution of diagnoses in cases
and controls in each group are summarized in Table 2.
For more information on sample selection, please see
Pedersen et al.44. The project was accepted by the Danish
ethical committee (approval number 1-10-72-287-12).
According to Danish law, all blood samples can legally be
stored without explicit informed consent. Their later use
for additional analysis are however conditional on
approvals of each separate project from the Research
Ethics Committee and the Danish Data Protection
Agency. According to the law, the use of samples for
research projects require informed consent, but the
Research Ethics Committee can waive this requirement if
the project is carried out with anonymous samples and
does not in any way imply health-related risks or may
burden the participants46.
Sample analysis, proteins
Two 3.2 mm disks from the DBSS were punched into
each well of polymerase chain reaction plates (Sarstedt,
72.1981.202). 130 µl extraction buffer (phosphate-buf-
fered saline containing 1% bovine serum albumin (Sigma
Aldrich #A4503), 0.5% Tween-20 (Merck Millipore
#8.22184.0500), and complete protease inhibitor cocktail
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(Roche Diagnostics #11836145001)) were added to each
well, and the samples were incubated for 1 h at room
temperature on a microwell shaker set at (900 rpm). The
extracts were manually moved to sterile Matrix 2D tubes
(Thermo Scientiﬁc, 3232) and stored frozen at −80 °C.
About 3 years later, samples were thawed and analyzed
using Meso-Scale plates printed and customized for the
project. Antibodies printed to the plates were speciﬁc for
BDNF, CRP, IL-18, IL-8, IgA, MCP-1, S100B, TARC, and
VEGF-A. All reagents, except for the reagents for S100B,
were purchased from MesoScale Diagnostics (MSD),
Maryland, US. The S100B assay was set up in-house
before custom printing using capture antibody (Sigma-
Aldrich, #S2532) and detection antibody (DAKO,
#Z0311). Calibrators were custom made by MSD. The
plates and calibrators were made in one batch to mini-
mize assay variations. Controls were made in-house from
part of the calibrator solution in one batch, aliquoted in
portions for each plate and stored at −20 °C until use. The
samples were prepared on the plates as recommended
from the manufacturer, and were immediately read on the
QuickPlex SQ 120 (MSD, MA, USA). Analyte con-
centrations were calculated from the calibrator curves on
each plate using 4PL logistic regression using the MSD
Workbench software.
Sample analysis, genotyping
Array genotyping of all samples was made at the Broad
Institute (Boston, MA, USA) using Inﬁnium PsychChip
v1.0 array (Illumina, San Diego, CA, USA), as previously
described44.
Analytical characterization
Intra-assay variations were calculated from 40 mea-
surements of a pool of the same control sample on the
same plate. Inter-assay variations were calculated from
controls analyzed on each plate during the sample ana-
lysis, 131 plates in total. Limit of detections were cal-
culated as 2.5 standard deviations from repeated
measurements of the zero calibrator. The higher detec-
tion limits were deﬁned as the highest calibrator
concentrations.
Preanalytical variation
To validate the stability of the samples during sto-
rage, we randomly selected 16 samples stored in the
biobank since 1982, since 1990, since 2000, since 2010,
and 16 fresh samples only 3–4 days old (from 2016).
After extracting the samples and adding them to the
MSD-plates, the rest of the extracts were frozen for
2 days, thawed and measured as described above to
imitate the freeze–thaw cycle of the samples in
the study.
Table 1 Demographic data for cases and controls
Cases Controls
Number in each group
Schizophrenia (ICD-10 F20) 1969 2681
Bipolar disorders (ICD-10
F30–31)
641 2311
Affective disorders (ICD-10
F32–39)
641 2371
ASD (ICD-10 F84.0, −1, −5,
−8, −9)
801 2421
ADHD (ICD-10 F90.0) 751 2423
Gender distribution %male/%female
Schizophrenia 57/43 51/49
Bipolar disorders 40/60 51/49
Affective disorders 32/68 50/50
ASD 78/22 52/48
ADHD 73/27 52/48
Birth weight (median [IQR] in gram)
Schizophrenia 3450 [3105–3805] 3505 [3155–3840]
Bipolar disorders 3425 [3105–3762] 3500 [3155–3810]
Affective disorders 3428 [3089–3755] 3500 [3155–3805]
ASD 3520 [3159–3900] 3505 [3175–3866]
ADHD 3502 [3151–3859] 3505 [3175–3865]
Gestational age (median [IQR] in weeks)
Schizophrenia 40 [39–41] 40 [39–41]
Bipolar disorders 40 [39–41] 40 [39–41]
Affective disorders 40 [39–41] 40 [39–41]
ASD 40 [39–41] 40 [39–41]
ADHD 40 [39–41] 40 [39–41]
Gestational age (week range,%
of total)
25–33 34–37
38–44
25–33 34–37
38–44
Schizophrenia 1,6 7,2 91,2 0,8 6,7 92,5
Bipolar disorders 1,9 6,8 91,3 0,9 6,5 92,7
Affective disorders 1,9 5,5 92,6 0,6 6,5 92,7
ASD 0,9 8,3 90,8 1,0 6,7 92,3
ADHD 1,2 9,3 89,5 1,0 6,7 92,3
Age at diagnosis (median [IQR] in years)
Schizophrenia 21 [18–23]
Bipolar disorders 22 [19–25]
Affective disorders 19 [17–23]
ASD 10 [7–13]
ADHD 10 [8–15]
Demographic data for cases and controls divided into the different disorders
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Statistics
Multiple logistic regression assessment of association
between marker levels and diagnosis/phenotype: the
measured concentrations for each marker were log-
transformed (ln) and standardized by year using z-
scores, in order to accommodate possible changes across
the period. Each protein was analyzed on a continuous
scale. First and second degree-relatives were removed
(relatedness coefﬁcient >0.2) and principal component
analysis were used to adjust for population stratiﬁcation.
The relatedness coefﬁcient were calculated using KING
(v.1.9)47 on Inﬁnium PsychChip v1.0 array (Illumina, San
Diego, CA, USA) data after removal of INDELs and SNPs
within long-range disequilibrium regions48 or with a
missing-rate above 0.001. Population structure was
inferred using principal components analysis using
EIGENSOFT version 6.1.449 smartPCA on the complete
iPSYCH array dataset and outliers deﬁned using default
settings. Because the distribution of gender between cases
and controls were not equal and due to gender-speciﬁc
expression of some markers, we adjusted for gender in the
statistical analysis. We also initially adjusted for gesta-
tional age and age in days of the newborns when the
samples were drawn. The last two factors did not make
any difference in the statistical analysis, and the results
presented are thus only adjusted for gender. To be sure
that gestational age did not have any inﬂuence on the
BDNF results, we made the same calculations on only
the term and premature cases and controls, respectively.
The statistical analysis was done with logistic regression
using R 3.3.150. Multiple testing correction was done
using Bonferroni correction at an α level of 0.05. A p value
was considered statistically signiﬁcant if p < 0.0056 (0.05/9
analytes).
Assessment of genetic inﬂuence on phenotype asso-
ciated marker levels using multiple linear regression: to
investigate whether genetic variation inﬂuences the mar-
ker levels we extracted genetic regions of interest, deﬁned
as a region containing all known NCBI refSeq51 transcript
variants and GTEx eQTL (tissue= brain), from imputed
data15. Genetic variants with call-percent <96% and
imputation score ⩽0.9 and highly correlated genetic var-
iants were removed based on the mean absolute correla-
tion with a cutoff >0.75 using Caret package52. A multiple
linear regression model was applied for all possible
combinations of genetic variants, including gender in all
models. Model selection was based on a minimum criteria
of p < 0.01 for all independent variables and a minimum
AIC and maximum adjusted R-squared.
Assessment of genetic clusters and association to mar-
ker levels and phenotype based on principal component-
and clustering analysis: to assess whether genetic variation
in regions of interest is associated with marker level or
phenotype “risk” we used principal components analysis
(R stats 3.5.1) to represent the most genetic variability in
two-dimensions and cluster the result using K means
clustering. The optimal k was deﬁned by pre-analysis of
total within sum of square minimization (R factoextra
1.0.5). Only complete observations were included in the
analysis. The assessment of the association between
clusters and marker levels was done using multiple linear
regression modeling and the association between clusters
and phenotype using multiple logistic regression.
The amount of degradation of the different analytes was
calculated with a MannWhitney nonparametric test using
GraphPad Prism 7.03 (GraphPad Software, Inc., La Jolla,
CA, USA).
The samples were barcoded in the neonatal screening
where we did not have any knowledge of the children.
These barcodes were used during sample analysis and
cleaning of data, thus the investigators did not have any
knowledge about case and control status.
Results
Newborns later diagnosed with ASD had signiﬁcantly
decreased levels of the neurodevelopmental factor BDNF.
In addition, there was a tendency toward decreased con-
centrations of all neurodevelopmental factors and
Table 2 Distribution of diagnosis in cases and controls
Case diagnosis → Schizophrenia Bipolar disorders Affective disorders ASD ADHD
Add. diagnosis ↓ Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls
Schizophrenia 100 0 4.4 0.5 4.7 0.5 1.0 0.4 0.9 0.4
Bipolar disorders 3.0 0.3 100 0.1 0 0.3 0.1 0.2 0.5 0.2
Affective disorders 33.4 2.5 100 2.7 7.4 1.9 7.5 1.9
ASD 6.6 0.8 5.3 0.7 4.4 0.7 100 1.2 19.0 1.3
ADHD 8.3 0.8 12.0 0.7 6.7 0.8 21.8 0.9 100 0.9
Only case diagnosis 57.3 0.0 80.3 0.1 85.5 2.2 71.2 0.9 74.0 0.7
The numbers are shown as percentage of cases and controls of each diagnostic group shown in the top row that also have the diagnosis in the left column
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increased concentrations of inﬂammatory markers, but
the statistical signiﬁcance for the other biomarkers dis-
appeared after Bonferroni corrections (Fig. 1). Figure 2
shows the calculated z-scores for BDNF for ASD-cases
and controls per year. Dividing the samples in only the
term and premature cases and controls, respectively, to be
sure that gestational age did not have any inﬂuence on the
results, did not change the results (results not shown).
When performing pairwise correlation for the ASD
cases, BDNF had a signiﬁcant positive correlation with the
other neurodevelopmental factors, VEGF and S100b, and
with the inﬂammatory/infection markers IgA and TARC.
The correlation with CRP was negative (Supplementary
Fig. 1). There were no differences in correlation between
females and males, nor between cases and controls,
respectively (data not shown). There was no correlation
between age at ASD diagnosis and BDNF level (data not
shown).
A total of 122 genetic variants SNPs in the BDNF region
(GRCh37:chr11: :27674440–27745605) was extracted, and
after ﬁltering on imputation score and call-percent, 98
remained and were reduced to 12 after removing corre-
lated (>0.75) variants. The best ﬁt model, according to
described criteria (R2= 0.042, F(2/2386)= 53.62, p < 2.2e
−16) included refSNP ID:rs142615576 (T/C) (β= 0.27,
p= 5.93e–5). However, rs142615576 explained only
0.75% of the variance and did not signiﬁcantly contribute
to the predictive ability of ASD in the logistic model
(rs142615576, p= 0.40). The cumulative proportion of
BDNF variance captured by principal component 1 and 2
was 89%, and the optimal k was estimated to 6 for the 98
variants included in the analysis. There was no signiﬁcant
correlation between the BDNF levels and any of the 6
clusters after correcting for multiple testing. Nor had the
clusters a predictive value for ASD in a logistic regression
model (data not shown).
We did not ﬁnd any signiﬁcant correlations between
ADHD, schizophrenia, bipolar-, and affective disorders
and the different biomarkers after Bonferroni corrections
(Supplementary Figs. 2–5). The measured concentrations
without any adjustments of all biomarkers for the differ-
ent disorders are shown as box-plots in Supplementary
Fig. 6.
Fig. 1 Forest plot for ASD. The ﬁgure shows calculated odds-ratios
(OR with 95% conﬁdence intervals) and p values for each marker.
There was decreased OR for developing ASD with increasing level of
BDNF. OR for developing ASD with low BDNF was 1/0.87 (1/0.95–1/
0.8)= 1.15 (1.05–1.25)
Fig. 2 BDNF Z-scores for ASD cases and controls. The concentrations were standardized by year in cases (orange boxes) and controls (blue boxes)
using z-scores. The ﬁgure shows median BDNF z-scores with 25–75th percentile (box), 1.5 × (25–75th) (vertical lines) and upper and lower
values (dots)
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Analytical performance and sample stability
Median intra assay variation was 3.3% and median inter
assay variation was 13.3%. Supplementary Table 1 shows
assay variations and limit of detections for all analytes,
and mean concentrations measured for all samples.
After being freezed and thawed once after extraction,
we found the analytes to be relatively stable. BDNF, IL-18,
S100B, and VEGF-A were signiﬁcantly decreased overall if
the extracts were freeze-thawed once, but mainly in the
oldest samples. Generally, the analytes seem to be more
fragile to a freeze–thaw cycle after more than 15 of years’
storage before the extraction. Overall, there was con-
siderable degradation of the analytes over the years, but all
analytes were measurable in the samples even after 30
years of storage (Supplementary Table 2).
Discussion
This is to our knowledge the largest study ever reported
regarding biomarkers in newborns later diagnosed with
mental disorders. The most signiﬁcant ﬁnding was the
association between later diagnosis of ASD and decreased
neonatal blood levels of BDNF.
BDNF is the main neurotrophic cytokine in the central
nervous system. It contributes to pre- and postnatal brain
development53; by promoting neuronal growth, differ-
entiation, and survival54, and by its potent effects on
synaptic and structural plasticity55. BDNF is present both
at pre- and postsynaptic sites, facilitating the release of
neurotransmitters, and promoting the function of ion-
transmitters and NMDA receptors56. Overall, BDNF
appears to strengthen excitatory (glutamatergic) synapses
and weaken inhibitory (GABAergic) synapses54. Outside
the brain, megakaryocytes (cells that produce blood pla-
telets), salivary glands, and endothelial cells produce
BDNF57. Blood platelets store most of the blood BDNF
and release BDNF upon activation at the site of traumatic
injury to facilitate the repair of peripheral nerves or other
tissues where it binds to tropomyosin-related kinase
receptor type B (TrkB) with high afﬁnity, and pan neu-
rotrophin receptor of p75NTR with low afﬁnity58. BDNF
is secreted from secretory vesicles, partly constitutively
but mainly stimulation- and activity-dependent59. Animal
studies have shown that BDNF can cross the blood brain
barrier both ways60. Thus, concentrations measured in the
blood are most probably correlated with concentrations in
the brain.
The decreased levels of BDNF that we found in DBSS
from newborns who later develop ASD concur with the
ﬁndings in a smaller study (414 ASD, 820 controls) on
DBSS from the Danish Neonatal Screening Biobank61,
although there may be some overlap of the cases between
the two studies. An earlier small study on DBSS in new-
borns has shown increased levels of BDNF compared to
controls62. This was a small study (60 ASD and 54
controls) based on single antibody detection, and the
authors have not been able to reproduce their results
using another analytical method63. Another small study
(84 ASD and 159 controls) on DBSS from newborns
found no difference in BDNF levels in ASD cases com-
pared to controls64. The DBSS was drawn from newborns
1–2 days after birth compared to 5–7 days in our study.
Thus, both study size and sampling time can probably
explain the different results. A study on ASD children age
0–19 years old has shown that ASD cases age 0–9 years
old have lower serum BDNF-levels compared to controls,
whereas the age 10–19 year old ASD cases have higher
levels than the controls65. A meta-analysis of 20 studies
analyzing blood BDNF levels in children that have already
been diagnosed with ASD (887 cases, 901 controls)
reported higher levels of BDNF in ASD cases than con-
trols56. Thus, the BDNF expression seems to be delayed in
the ASD cases. When comparing results from different
immunoassays, we have to be aware that antibodies in
various assays may capture different parts of the BDNF
molecule, thus this may also explain differences seen
when comparing studies. A study has described elevated
numbers of blood platelets in ASD cases (mean age 11.9
years)66, but we were not able to ﬁnd similar studies in
newborns. As blood platelets store BDNF58, this would be
relevant to explore in further studies. We do not know if
we are measuring the total BDNF in dried blood spot
samples, that is, if the platelet-bound BDNF is released, or
if we are only measuring the free BDNF. To further elu-
cidate the role of BDNF in the development of ASD it
would be relevant to investigate the expression levels of
TrkB, the receptor that induces the main effects of BDNF,
as well as pro-BDNF, the molecule that after cleavage
becomes the mature BDNF67.
Low-BDNF levels in newborns have also been asso-
ciated with growth restriction and delivery for medical
indications in the very preterm children68. This suggests
that the lower BDNF levels seen in newborn ASD cases
may be caused by less favorable pregnancy conditions.
BDNF correlated slightly negatively with CRP, while
other inﬂammatory markers and neurotrophic factors
correlated positively with BDNF (Supplementary Fig. 1).
The highest correlation was seen between BDNF and
VEGF-A. VEGF-A is a growth factor that stimulates
vasculogenesis and angiogenesis after stress, and it is an
essential factor for placental development69. VEGF-A
plays an important role in the growth and differentiation
of hematopoietic cells, which are the precursors to
megakaryocytes that produce both blood platelets and
BDNF70. Decreased blood levels of VEGF-A have also
been described after clinical presentation of ASD, both in
humans where VEGF-A levels were signiﬁcantly lower in
autism cases compared to Retts syndrome71, and in VPA-
induced autism mouse models72. However, this is not
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corroborated in another study in humans73. Genetic
polymorphisms leading to higher levels of circulating
VEGF-A have been associated with larger gray and white
matter brain volume and a higher cerebral blood ﬂow74.
Transplantation of VEGF-A producing cells has been
shown to reduce neonatal brain damage after hypoxia-
ischemia in rats75. Low levels of VEGF-A at birth may
indicate that angiogenesis and vasculogenesis are not
sufﬁciently stimulated, leading to impaired development
of the immature newborn brain. It is possible that the low
VEGF-A-levels are the cause for the observed lower
BDNF-levels.
Patients with mental and neurodegenerative disorders
often have reduced BDNF blood (and brain) levels and
frequently exhibit neuroinﬂammation76. We found a trend
toward elevated levels of inﬂammatory markers and
reduced levels of neurodevelopmental markers in ASD
cases. To further study this trend, we analyzed the pairwise
correlation of BDNF with all other markers ﬁnding a
positive correlation of BDNF with TARC and IgA and a
negative correlation with CRP. Since all correlations were
marginal, and no signiﬁcant difference was found between
cases and controls, our data cannot contribute in explain-
ing the role of inﬂammation in the development of ASD.
It is known that ASD has genetic predispositions18, but
we could not ﬁnd them in the coding regions for BDNF.
Haploinsufﬁciency of BDNF, present in human WAGR/
11p13 deletion syndrome77, is associated with ASD,
reduced adaptive behavior and cognitive functioning,
social impairment, and higher score in the autism diag-
nostic test ADI-R. In the present study it was not possible
to correlate newborn BDNF blood levels with the trajec-
tory of ASD. However, the BDNF level did not correlate
with the age at diagnosis. ASD subgroups—particularly
those with regression of cognitive and social functions vs.
the ASD patients without such regression—have been
shown to differ with respect to biomarker proﬁles78. This
would be an important subject of further study.
It appears that ﬁndings of increased or decreased blood
levels of brain development factors associated with ASD
are dependent on the time of blood sampling. That is, if the
samples are drawn a few days after birth during a period of
signiﬁcant brain development and prior to recognizable
symptoms, or if they are drawn later in life when the dis-
ease is obvious and debilitating, the relationship between
cases and controls can change. Common for most studies
are abnormal proﬁles of neuro-developmentally important
factors in children with ASD, both before and after diag-
nosis. The fact that BDNF is decreased a few days after
birth suggests that the neurodevelopmental change starts
already in utero. The identiﬁcation of biomarkers that
could identify the younger siblings of ASD children that is
of high risk for ASD might help in being able to start early
treatment79. This is a major focus for ASD research.
The clear demonstration of reduced BDNF in blood in
newborn children that develop ASD deﬁnes the BDNF
associated pathways as a very promising area for further
research80. It may also help identifying a long-sought marker
for high ASD risk in, e.g., younger siblings of ASD children.
We could not ﬁnd any signiﬁcant neonatal biomarkers
for schizophrenia, ADHD, bipolar- or affective disorders.
More clear-cut cases with only one diagnose would be
optimal, as the biomarkers for one disorder may be hid-
den by biomarker noise from another disorder. Further,
some of the controls may be cases that has just not been
diagnosed yet. Especially for the disorders mainly diag-
nosed in adults, it is possible that the biological changes
has not appeared yet a few days after birth.
Assay performance and stability
We found the assay to be very stable with generally small
analytical variations. Some of the analytes were signiﬁcantly
degraded after one freeze–thaw cycle, and the analyte con-
centrations were signiﬁcantly decreased after more than 30
years of storage. The ﬁlter paper was changed in 1989 from
“Schleicher & Schuell grade 2992” to “Schleicher & Schuell
grade 903”, which can explain some of the lower con-
centrations measured in the samples from 1980s, as it is
known that there is a 17% difference in blood absorption
between the two different papers81. In 2010 the paper was
changed from “Schleicher & Schuell 903” to “Ahlstrom
grade 226”, but these two paper qualities have been shown
to absorb blood equally well82. In this study, we have
therefore matched cases and controls on birth year, and all
samples were treated identically with the same number of
freeze–thaw cycles and the same number of days stored
after extraction. In this way, we were able to both accom-
modate the different papers used and the degradation of
analytes over the years. Further, all analyte concentrations
were stratiﬁed by year using z-scores in the statistical cal-
culations, to avoid that analyte degradation could have any
inﬂuence on the statistical results.
Final remarks
The strengths of this study are the large sample size and
the homogeneity of the samples since all samples were
drawn from the newborns at the same time after birth. The
sample matrix has no variation since the samples are dried
on the same kind of ﬁlter paper at room temperature.
Further strengths are that the Danish Newborn Screening
Biobank is population based, and this study includes sam-
ples from a broad cross section of society regardless of social
and economic status. A weakness is that we only have one
sample per person, thus we are only able to look at bio-
markers at one time window. This means that we cannot see
all potential neonatal biomarkers as some may already have
disappeared and others have not yet appeared. For most
markers, we do not know if the origin is fetal or maternal.
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There was some overlap in diagnoses between cases and
controls, but not more than in a background population.
These overlaps may reduce or twist the signiﬁcance of the
found biomarkers. Some cases had more than one diagnosis,
thus the biomarkers for one disorder may be hidden by
biomarkers for another disorder.
We found decreased blood levels of BDNF, an impor-
tant factor for the developing brain, in blood from new-
borns later diagnosed with ASD. This encourages further
research in the role of neurotrophic factors for the etiol-
ogy of ASD.
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